Session » Pediatric Rheumatology – Clinical Poster I: JIA

Date: Sunday, November 13, 2022

Time: 9:00AM-10:30AM

Meeting: ACR Convergence 2022

9:00AM-10:30AM: Abstract Number: 0856

A Cross-Sectional Description of Physical Activity (PA) in Children with Juvenile Idiopathic Arthritis (JIA): The LEAP Study (Linking Exercise, Activity, and Pathophysiology in Canadian Children with Arthritis)

9:00AM-10:30AM: Abstract Number: 0874

A Tale of Many Canadas: Associations of Ethnicity with Juvenile Idiopathic Arthritis Categories and Disease Severity at Presentation in a Multicultural Universal Healthcare Setting: Results from ReACCh-Out

9:00AM-10:30AM: Abstract Number: 0878

A United States Nationwide Analysis of Total Knee Arthroplasty in Patients < 21 Years Old

9:00AM-10:30AM: Abstract Number: 0864

Baseline Clinical and Laboratory Features of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease (SJIA-LD) Cohort

9:00AM-10:30AM: Abstract Number: 0869

Behavioral Health Outcomes and Social Determinants of Health in Children with Juvenile Arthritis Compared to Children with Diabetes and Healthy Children

9:00AM-10:30AM: Abstract Number: 0873

Celiac-Associated Arthritis: Clinical Features, Treatment, and Outcomes

9:00AM-10:30AM: Abstract Number: 0855

Change in Short Term Outcomes Following Tolerated Disease Activity Level for Individuals with Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry

9:00AM-10:30AM: Abstract Number: 0860

Characteristics of Transitioning JIA Patients: Who Is Arriving on the Adult Rheumatologists’ Doorsteps?

9:00AM-10:30AM: Abstract Number: 0857

Consensus-Driven Definition for Unequivocal Sacroiliitis on Radiographs for Classification in Juvenile Spondyloarthritis

9:00AM-10:30AM: Abstract Number: 0852

Development, Refinement and Weighting of Candidate Criteria for Axial Disease in Juvenile Spondyloarthritis: An International Collaboration

9:00AM-10:30AM: Abstract Number: 0863

Effect of Glucocorticoids on Patient Reported Outcomes in Patients Started on a Biologic Consensus Treatment Plan for the ‘First Line Options for Systemic JIA Treatment’ (FROST) Study

9:00AM-10:30AM: Abstract Number: 0879

Golimumab for Treatment of Polyarticular Juvenile Idiopathic Arthritis – Safety and Effectiveness Updates from a Comparative Study

9:00AM-10:30AM: Abstract Number: 0880

Impact of Characteristic Inflammatory and Structural Imaging Lesions on Expert Classification of Axial Juvenile Spondyloarthritis

9:00AM-10:30AM: Abstract Number: 0862

Impact of the COVID-19 Pandemic on the Management of Juvenile Idiopathic Arthritis: An Analysis of National United States Administrative Claims Data

9:00AM-10:30AM: Abstract Number: 0861

Incidence of Juvenile Idiopathic Arthritis During the COVID-19 Pandemic: An Analysis of National United States Administrative Claims Data

9:00AM-10:30AM: Abstract Number: 0872

Incidence, Risk Factors, and Outcomes of Eosinophilia on IL-1 and IL-6 Inhibitors in Systemic and Non-Systemic Juvenile Idiopathic Arthritis

9:00AM-10:30AM: Abstract Number: 0876

Investigation of Predictive Factors for Active Disease Status Within 24 Months of Juvenile Idiopathic Arthritis Diagnosis

9:00AM-10:30AM: Abstract Number: 0870

Knee Acoustic Emissions as a Noninvasive Biomarker of Articular Health in Juvenile Idiopathic Arthritis

9:00AM-10:30AM: Abstract Number: 0877

Neutrophils Extracellular Traps Formation May Serve as a Biomarker for Disease Activity in Oligoarticular Juvenile Idiopathic Arthritis

9:00AM-10:30AM: Abstract Number: 0865

Opioid Use in Youth with Inflammatory Bowel Disease (IBD)-related Arthritis

9:00AM-10:30AM: Abstract Number: 0854

Outcome of Uveitis in Juvenile Idiopathic Arthritis and Spondyloarthritis Patients – a 5-year Follow up Study

9:00AM-10:30AM: Abstract Number: 0866

Outcomes of Children with Uveitis Associated with Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (ADNIV) Treated with Methotrexate and Infliximab

9:00AM-10:30AM: Abstract Number: 0850

Outcomes of Patients with Juvenile Idiopathic Arthritis Following Failure of Initial Tumor Necrosis Factor Inhibitor Medication in the Childhood Arthritis and Rheumatology Research Alliance Registry

9:00AM-10:30AM: Abstract Number: 0858

Predicting the Occurrence of Drug-Free Inactive Disease Two Years After Diagnosis of Non-Systemic Juvenile Idiopathic Arthritis

9:00AM-10:30AM: Abstract Number: 0875

Predictive Biomarkers of Tofacitinib Response and Disease Activity in Juvenile Idiopathic Arthritis Subtypes: A Longitudinal Study

9:00AM-10:30AM: Abstract Number: 0867

Regulatory Haplotype of CXCR4 Is Associated with sJIA and Corelates with Enhanced Neutrophil and CD14+ Monocyte Migration

9:00AM-10:30AM: Abstract Number: 0853

Reliability of MRI Lesions Comprising the Preliminary OMERACT Juvenile Idiopathic Arthritis MRI Score (OMERACT JAMRI-SIJ): What Is the Impact of Systematic Reader Calibration?

9:00AM-10:30AM: Abstract Number: 0851

Responsiveness of Patient-Reported Physical Function Measures in Juvenile Arthritis

9:00AM-10:30AM: Abstract Number: 0868

Spondyloarthritis and Neonatal Factors Affecting the Gut Microbiome

9:00AM-10:30AM: Abstract Number: 0859

Systemic Juvenile Idiopathic Arthritis Associated Lung Disease in Europe

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].